CADILA HEALTHCARE LTD.
|
|
- Miles Scott
- 8 years ago
- Views:
Transcription
1 4 ISIN: INE010BO1019 FEBRUARY 22 nd 2014 STOCK DETAILS Sector CADILA HEALTHCARE LTD. BSE Code Face Value 5.00 Result Update: Q3 FY14 Pharmaceuticals 52wk. High / Low (Rs.) / Volume (2wk. Avg ) Market Cap ( Rs in mn ) ANNUAL ESTIMATED RESULTS (A*: ACTUAL / E*: ESTIMATED) Years FY13A FY14E FY15E Net Sales EBITDA Net Profit EPS P/E SHAREHOLDING PATTERN (%) 1 YEAR COMPARATIVE GRAPH CADILA HEALTHCARE LTD. BSE SENSEX Recommend BUY CMP Target Price Highlights Cadila Healthcare Ltd. has posted 81% jump in its net profit from Rs mn to Rs mn in current December quarter. Total Income i.e net sales of the company improved by 16.68% and stood at Rs mn compared to Rs mn in Q3 FY13. EBDITA of the company stood at Rs mn rising by 13.23% YOY and the total expenditure rose by 16% YOY at Rs mn in Q3 FY14. PBT rose at even higher rate of 35% from Rs mn to Rs mn in current December quarter. Zydus Cadila has received the final approval from the USFDA to market Sirolimus Tablets 0.5 mg with 180 days of marketing exclusivity, Etodolac Extended- release Tablets for treatment of Juvenile arthritis, rheumatoid arthritis & osteoarthritis and Bupropion Hydrochloride Extended- release Tablets USP which is in the anti-depressants segment. Finance costs in the current quarter fell by 52% compared to the corresponding quarter in the previous year. In the present quarter, the company s business in the US and Europe was up by 61% and 6% respectively. Exports to emerging markets grew by 30% at Rs. 832 mn in Q3 FY14. During the quarter, the company filed 31 additional ANDAs with the US FDA taking the cumulative ANDA filings for the period April- December 2013 to 49. Net Sales and PAT of the company are expected to grow at a CAGR of 14% & 10% over 2012 to 2015E respectively. PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND COMPANY NAME (Rs.) Rs. in Mn. (Rs.) Ratio Ratio (%) Cadila Healthcare Ltd Cipla Ltd Sun Pharmaceuticals Ltd Divis Laboratories
2 Analysis & Recommendation- BUY Cadila Healthcare Ltd. is on the rise from the last six months. The scrip has risen 1.5 times since last September As per market expectations, Net Profit galloped by 81% YOY at Rs mn against Rs mn in the corresponding quarter of the previous year. Net Sales grew at 17% and stood at Rs mn in Q3 FY14 compared to Rs mn in Q3 FY13. Expenses rose by 16% YOY at Rs mn in the current December quarter. With low expenditure and finance costs declining by 52% (Rs mn)YOY, company reported Profit Before Tax of Rs 2360 mn compared to Rs mn in the same period previous year, rising by 35% YOY. Cadila s domestic business has grown by 3.8% whereas exports grew by 38% YOY. Global Business in US, Emerging Markets and Europe rose by 61%, 30% and 6% respectively. During the quarter, the company filed 31 additional ANDAs with the US FDA taking the cumulative ANDA filings for the period April- December 2013, to 49. During the December quarter, the company received US FDA approval for initiating Phase I clinical trials of ZYDPLA1 a novel, next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes. In addition to that, Cadila Healthcare has received the final approval from the USFDA to market Sirolimus Tablets 0.5 mg with 180 days of marketing exclusivity, Etodolac Extended- release Tablet for treatment of Juvenile arthritis, rheumatoid arthritis & osteoarthritis and Bupropion Hydrochloride Extendedrelease Tablets USP which is in anti-depressants segment. Cadila Healthcare with its strong fundamentals is poised for higher growth with low debt equity ratio of 0.88 as on 31 st March Thus we recommend BUY for the scrip with target price of Rs COMPANY PROFILE Zydus Cadila, a global healthcare provider was founded by Late Mr. Ramanbhai B. Patel in In 1995, the group restructured its operations and emerged with a new identity under the aegis of Zydus group as Cadila Healthcare Ltd. Cadila Healthcare is the flagship company of Zydus Cadila group. The group, headquartered in Ahmedabad develops, manufactures and markets broad range of healthcare products ranging from API to formulations, animal health products and cosmeceuticals. The Zydus Cadila group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets. Zydus Cadila is a leading player in the cardiovascular, gastrointestinal and women's healthcare segments. The group has strong presence in respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and nephrology segments. It has been able to maintain overall position and market share through faster growing lifestyle segments. The group has several in-licensing alliances with global multinationals such as Schering AG, Boehringer Ingelheim, Viatris, etc. The portfolio of products of the group is over 200 which are marketed by a specialized field force of about 3,000. With one of the strongest distribution channels in the industry, the group reaches out to 1,00,000 chemists and serves 2,00,000 doctors including physicians, specialists and super specialists.
3 Zydus Wellness Ltd., spearheads the group's presence in the consumer and wellness segment. The products of the company comprises of Sugar Free Gold India s No.1 sweetener with a market share of over 70%, Sugar Free Natura a zero calorie sucralose based sugar substitute, Sugar Free D lite a low calorie healthy drink and Nutralite a premium cholesterol-free table spread. Nutralite has emerged as the second largest brand in the category of butter and butter substitutes. In addition to that the company also caters to the skincare segment with its Everyuth and Dermacare brands, which occupy a unique distinction of being a skincare brand from a healthcare company. Enriched with the power of natural ingredients, EverYuth has a strong presence in advanced skincare segments like soap-free, face washes, face masks, scrubs etc. Quarterly Highlights Q3 FY14 Months Dec -13 Dec-12 % Change Total Income % Net Profit % Net Profit Margin 9.93% 6.41% 352 BP EBITDA % EBITDA Margin 16.46% 16.96% (50BP) Other Income % Profit Before Tax % Total income of the company rose by 17% and stands at Rs mn from Rs mn in Q3 FY13. Net profit of the company galloped at 80% to Rs mn from Rs mn. EBDITA increased by 13.23% from Rs mn to Rs mn in Q3 FY14. EBDITA margin fell by 50 basis points. Net profit margin jumped by 352 basis points mainly due to decline in tax expenditure and finance costs. Other income of Cadila Healthcare Ltd rose by 89% from Rs mn to Rs mn in current September quarter. Profit Before Tax also rose by 35.57% at Rs mn in Q3 FY14. Break up of Expenditure Rs. In Mn Q3 FY14 Q3 FY13 CHNG % Material Consumed % Stock in Trade % Employee Benefit Exp % Dep. & Amortz. Exp % Other Exp %
4 Cost of material consumed rose by just 3% at Rs mn. Purchase of stock in trade rose by 36.92% from Rs mn to Rs mn in Q3 FY14. The highest rise in expenditure was from stock in trade and employee benefit expenses by 37% and 12.44% respectively. Employee benefit expenses rose from Rs mn to Rs mn in Q3 FY14. Depreciation and amortization fell by 1.14% to Rs mn from Rs mn in Q3 FY13. Other expenses grew by 7.31% at Rs mn in the current December quarter. Revenue Segment Domestic sales (In Rs. Mn) Q3 FY14 Q3FY13 % change Formulations % API % Wellness % Animal Health and Others % Total Domestic Sales % Important Updates (In Rs. Mn) Q3 FY14 Q3 FY13 % change Exports % Formulations: US % Europe % Japan (19.44%) Brazil (4.05%) Mexico % Emerging markets % API: % Animal Health & Others: % Zydus Cadila received the final approval from the USFDA to market Sirolimus Tablets 0.5 mg with 180 days of marketing exclusivity. As per IMS data in 2013, the sales of Sirolimus 0.5mg was estimated at $11.7 million and the total market for Sirolimus was approximately $203.8 million. The group also received Duloxetine delayed release capsules in different strengths of 20 mg, 30 mg and 60 mg. The sales for Duloxetine were estimated at $5.5 billion in While Sirolimus tablets are immunosuppressant
5 drugs used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment. During the quarter, the company filed 31 additional ANDAs with the US FDA taking the cumulative ANDA filings for the period April-December 2013, to 49. In Mexico, the company launched 2 new products during the quarter, taking the cumulative launches to 6 and filed 8 dossiers with the Mexican regulatory authority, taking the cumulative filings to 36. The company filed 9 dossiers with the ANVISA, taking the cumulative filings to 113. In the European market, the company received the approval for 15 new product dossiers and launched 2 new products in France and 3 new products in Spain. 7 new products were launched in the different Emerging Markets during the quarter. During the quarter, the company received the US FDA approval for initiating Phase I clinical trials of ZYDPLA1 a novel, next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes. For Biosimilars, the company initiated Phase III clinical trials for one of the mabs and completed Phase I clinical trials completed for both the novel biologics, PEGEPO and Rabimabs. Zydus Cadila has received the final approval from the USFDA to market Etodolac Extended- release Tablet USP, 400 mn, 500 mn and 600 mg. The drug is prescribed for treatment of Juvenile arthritis, rheumatoid arthritis and osteoarthritis. Zydus Cadila has received the final approval from the USFDA to Bupropion Hydrochloride Extended- release Tablets USP (XL) in the strength of 300 mg. The drug falls in the anti-depressants segment. Cadila Healthcare Limited and Zydus Pharmaceuticals (USA), Inc. have entered into an agreement in principle with Warner Chilcott Company LLC to settle all outstanding patent litigation related to Asacol HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of definitive documentation. Under the terms of the agreement in principle, Warner Chilcott Company will grant Cadila and Zydus a royalty bearing license to market a generic version of Asacol HD beginning on November 15, 2015 or earlier under certain circumstances, following receipt by Zydus of final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for generic Asacol HD. Alternatively, if Zydus does not receive FDA approval of its generic Asacol HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Asacol HD beginning on July 1, 2016.
6 FINANCIAL STATEMENTS & ESTIMATIONS (CONSOLIDATED) Balance Sheet as on March 31 st, 2012 to 2015E (A*- Actual, E* -Estimations & Rs. In Millions) Cadila Healthcare Ltd FY12A FY13A FY14E FY15E EQUITY AND LIABILITIES: Shareholders Funds: Share Capital Reserves and Surplus Net worth (a) Minority Interest (b) Non-Current Liabilities: Long-term borrowings Deferred Tax Liabilities [Net] Other Long Term Liabilities Long Term Provisions Long term liabilities (c) Current Liabilities: Short-term borrowings Trade Payables Other Current Liabilities Short Term Provisions Current Liabilities (d) Total Liabilities (a+b+c+d) ASSETS: Non-Current Assets: Tangible Assets Goodwill on consolidation (net) Non Current Investments Long Term Loans and Advances Total Non Current Assets (e) Current Assets: Current Investments Inventories Trade Receivables Cash and Bank Balances Short Term Loans and Advances Other Current Assets Total Current Assets (f) Total Assets (d+e)
7 Annual Profit & Loss Statement for the period of 2012to 2015E Value(Rs.in.mn) FY12A FY13A FY14E FY15E Description 12m 12m 12m 12m Net Sales Other Income Total Income Expenditure Operating Profit Interest Gross profit Depreciation Profit Before Tax Tax Profit After Tax Minority Interest Net Profit Equity capital Reserves Face value EPS Quarterly Profit & Loss Statement for the period of 30 th June, 2013 to 31 st March, 2014E Value(Rs.in.mn) 30-Jun Sep Dec Mar-14E Description 3m 3m 3m 3m Net sales Other income Total Income Expenditure Operating profit Interest Gross profit Depreciation Profit Before Tax Tax Profit After Tax Minority Interest Net Profit Equity capital Face value EPS
8 Ratio Analysis Particulars FY12A FY13A FY14E FY15E EPS (Rs.) EBITDA Margin (%) 21.60% 18.29% 16.85% 17.28% PBT Margin (%) 15.09% 12.76% 12.85% 13.56% PAT Margin (%) 12.94% 10.88% 11.30% 11.60% P/E Ratio (x) ROE (%) 26.47% 22.75% 21.22% 19.34% ROCE (%) 28.25% 23.52% 20.64% 19.30% Debt Equity Ratio EV/EBITDA (x) Book Value (Rs.) Charts P/BV
9 INDUSTRY OVERVIEW Indian pharmaceutical industry is a branded generics market, growing at a CAGR of 12.5% over the past five years. The pharmaceutical industry is expected to grow at a fast rate on the basis of high growth in exports and stable domestic market. Growth in the domestic pharma is mainly driven by improved medical infrastructure, increase in per capita income and increase in health insurance coverage. The export market of Indian pharmaceutical industry is driven by patent expiries of branded drugs all over the world. Pharma industry in India is highly fragmented and the entry of more players has made the industry highly competitive. At present there are 250 large units and 8000 small scale units. Before 1970, India was dependent on foreign companies for various drug requirements, but now India is completely self sufficient and imports are done only due to quality and economic reasons and not because of non- availability of pharmaceutical products. Indian pharmaceutical industry has undergone a wave of mergers and acquisitions. Starting from Ranbaxy acquired by Daiichi Sankyo, Shanta Biotech by Sanofi-aventis, Primal Healthcare by Abbot to name a few. The pharma sector has attracted foreign direct investments (FDI) worth US$ 11, million during April 2000 to April 2013, according to the latest data published by Department of Industrial Policy and Promotion (DIPP). India ranks 4 th worldwide and accounts for 8% of world's production by volume and 1.5% by value. It ranks 17th in terms of export value of bulk actives and dosage forms. The Indian pharmaceutical industry will continue its growth story and is expected to grow at percent in and touch $29 billion by OUTLOOK AND CONCLUSION At the current market price of Rs the stock P/E ratio is at x FY14E and x FY15E respectively. Earning per share (EPS) of the company for the earnings for FY14E and FY15E is seen at Rs and Rs respectively. Net Sales and PAT of the company are expected to grow at a CAGR of 14% and 10% over 2012 to 2015E respectively. On the basis of EV/EBITDA, the stock trades at x for FY14E and x for FY15E. Price to Book Value of the stock is expected to be at 5.10 x and 4.16 x respectively for FY14E and FY15E. We recommend BUY in this particular scrip with a target price of Rs for Medium to Long term investment.
10 Disclaimer: This document prepared by our research analysts does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable but do not represent that it is accurate or complete and it should not be relied on as such. Firstcall India Equity Advisors Pvt. Ltd. or any of it s affiliates shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This document is provide for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision.
11 Firstcall India Equity Research: C.V.S.L.Kameswari Pharma U. Janaki Rao Capital Goods B. Anil Kumar IT, Auto & FMCG Suhani Adilabadkar Pharma & Banking M. Vinayak Rao Diversified Firstcall India also provides Firstcall India Equity Advisors Pvt.Ltd focuses on, IPO s, QIP s, F.P.O s,takeover Offers, Offer for Sale and Buy Back Offerings. Corporate Finance Offerings include Foreign Currency Loan Syndications, Placement of Equity / Debt with multilateral organizations, Short Term Funds Management Debt & Equity, Working Capital Limits, Equity & Debt Syndications and Structured Deals. Corporate Advisory Offerings include Mergers & Acquisitions(domestic and cross-border), divestitures, spin-offs, valuation of business, corporate restructuring-capital and Debt, Turnkey Corporate Revival Planning & Execution, Project Financing, Venture capital, Private Equity and Financial Joint Ventures Firstcall India also provides Financial Advisory services with respect to raising of capital through FCCBs, GDRs, ADRs and listing of the same on International Stock Exchanges namely AIMs, Luxembourg, Singapore Stock Exchanges and other international stock exchanges. For Further Details Contact: 3rd Floor,Sankalp,The Bureau,Dr.R.C.Marg,Chembur,Mumbai Tel. : / / Telefax : info@firstcallindiaequity.com
PEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 170.30 Target Price 196.00 GEOMETRIC LTD Result Update (CONSOLIDATED): Q2 FY16 DECEMBER 17 th 2015 ISIN: INE797A01021 12 th h, 2013 Index Details Stock Data Sector IT Consulting & Software BSE
More informationBUY. KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16. CMP 226.50 Target Price 260.00. JANUARY 9 th 2015 SYNOPSIS ISIN: INE164B01022
BUY CMP 226.50 Target Price 260.00 KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16 JANUARY 9 th 2015 ISIN: INE164B01022 Index Details Stock Data Sector IT Software Products BSE Code 519602
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 196.40 Target Price 225.00 STYLAM INDUSTRIES LIMITED Result Update (PARENT BASIS): Q2 FY16 DECEMBER 16 th. 2015 ISIN: INE239C01012 12 th h, 2013 Index Details Stock Data Sector Plastic Products
More informationBUY RSWM LTD SYNOPSIS. CMP 292.20 Target Price 336.00. SEPTEMBER 1 st 2015. Result Update(PARENT BASIS): Q1 FY16
BUY CMP 292.20 Target Price 336.00 RSWM LTD Result Update(PARENT BASIS): Q1 FY16 SEPTEMBER 1 st 2015 ISIN: INE611A01016 Index Details Stock Data Sector Textiles BSE Code 500350 Face Value 10.00 52wk. High
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 514.75 Target Price 590.00 DOC CODE: FOTL_090220164_3 IGARASHI MOTORS INDIA LTD Result Update (PARENT BASIS): Q3 FY16 FEBRUARY 9 th 2016 ISIN: INE188B01013 12 th h, 2013 Index Details Stock Data
More informationBUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP 1677.00 Target Price 1880.00. SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010
BUY CMP 1677.00 Target Price 1880.00 ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16 SEPTEMBER 2 nd, 2015 ISIN: INE738I01010 Index Details Stock Data Sector IT & ITes BSE Code 532927 Face
More informationBUY. JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16. CMP 298.00 Target Price 340.00. DECEMBER 29 th 2015.
BUY CMP 298.00 Target Price 340.00 JYOTHY LABORATORIES LTD Result Update (CONSOLIDATED BASIS): Q2 FY16 DECEMBER 29 th 2015 ISIN: INE668F01031 12 th h, 2013 Index Details Stock Data Sector Household Products
More informationCMP: 1152.10 JUNE 2016 SWARAJ ENGINES LTD
Index Details SWARAJ ENGINES LTD Result Update (PARENT BASIS): Q4 FY16 Stock Data Sector Auto Parts & Equipment BSE Code 500407 Face Value 10.00 52wk. High / Low (Rs.) 1207.90/762.00 Volume (2wk. Avg.)
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 534.00 Target Price 615.00 TECH MAHINDRA LIMITED Result Update (CONSOLIDATED BASIS): Q2 FY16 NOVEMBER 19 th 2015 ISIN: INE669C01036 12 th h, 2013 Index Details Stock Data Sector IT BSE Code 532755
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 1077.50 Target Price 1200.00 BHARAT RASAYAN LTD Result Update (PARENT BASIS): Q2 FY16 DECEMBER 7 th 2015 ISIN: INE838B01013 12 th h, 2013 Index Details Stock Data Sector Agrochemicals BSE Code
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 296.50 Target Price 340.00 TRANSPORT CORPORATION OF INDIA LTD Result Update (PARENT BASIS): Q2 FY16 JANUARY 2 nd 2016 ISIN: INE688A01022 12 th h, 2013 Index Details Stock Data Sector Surface Transportation
More informationHINDUSTAN COMPOSITES LTD Result Update (PARENT BASIS): Q4 FY16
HINDUSTAN COMPOSITES LTD Result Update (PARENT BASIS): Q4 FY16 Index Details Stock Data Sector Auto Parts & Equipment BSE Code 509635 Face Value 10.00 52wk. High / Low (Rs.) 1567.00/750.00 Volume (2wk.
More informationMAITHAN ALLOYS LTD Result Update (PARENT BASIS): Q4 FY16
Index Details MAITHAN ALLOYS LTD Result Update (PARENT BASIS): Q4 FY16 Stock Data Sector Iron & Steel/Interm. Products BSE Code 590078 Face Value 10.00 52wk. High / Low (Rs.) 313.80/72.25 Volume (2wk.
More informationDr. Reddy s Q3 and 9M FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationAn integrated global healthcare company
An integrated global healthcare company 1 A Mission to create healthier communities globally Zydus Cadila is dedicated to life In all its dimensions. Our world is shaped by a passion for innovation, commitment
More informationSmruthi Organics Limited BSE Scrip Code: 590046
Smruthi Organics Limited BSE Scrip Code: 590046 Pharmaceuticals September 21, 2012 Equity Statistics Current Market Price Rs. 218.1 52 Week High / Low Rs. 273.9 / 155 Market Capitalisation Rs. crores 83.2
More informationPI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI
$Com panyname$ Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) HOLD PI Industries Ltd. Custom synthesis
More informationBUY. AARTI INDUSTRIES LTD Result Update (PARENT BASIS): Q2 FY16. CMP 521.15 Target Price 580.00. JANUARY 5 th. 2016. 12 th h, 2013 SYNOPSIS
BUY CMP 521.15 Target Price 580.00 AARTI INDUSTRIES LTD Result Update (PARENT BASIS): Q2 FY16 JANUARY 5 th. 2016 ISIN: INE769A01020 12 th h, 2013 Index Details Stock Data Sector Commodity Chemicals BSE
More informationFlexituff International Ltd. (FIL)
s $CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 (Wholly owned subsidiary of Bank of Baroda) Q2FY16 Result Review BUY Flexituff International Ltd. (FIL)
More informationHOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights
The case of missing sales growth Zydus Q3 net sales at Rs1.1 bn was up 3% on a like-to-like basis (Q3 15 had Rs 223 mn additional excise duty credit from prior periods), below our estimate of 6%. The company
More informationSphere Global Services Limited
Sphere Global Services Limited Date: 13 th January, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 3.95^ Face Value : ` 1 per share 52 wk High / Low : ` 9.35 / 31.1
More informationTable of Content. 1. Investment Highlights 03. 2. Company Profile 06. 3. Peer Group Comparison 09. 4. Financials 10. 5.
Oracle Financial Services Software (IFLEX) BUY CMP: Rs.2286.00 Date: November 18, 2009 Key Ratios: Particulars FY09 FY10E FY11E OPM(%) 27 34 33 NPM(%) 31 32 31 ROE(%) 20 17 15 ROCE(%) 19 19 17 P/BV(x)
More informationRAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16
RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS Earnings Presentation Q2 FY16 Company Overview COMPANY OVERVIEW Rajesh Exports Ltd. (REL) was incorporated in 1989. Currently REL is a leader
More informationSimplex Infrastructures
2QFY216 Result Update Infrastructure November 17, 215 Simplex Infrastructures Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq) Net
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 SPS Finquest Ltd CMP: 84.60 January 13, 2015 Stock Details BSE code 538402 BSE ID SPS Face value ( ) 10 No of shares
More informationSalzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment
$CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Salzer Electronics Ltd. Steady
More informationGujarat State Petronet Ltd. INR 135
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Oil & Gas RESULT UPDATE Gujarat State Petronet Ltd. INR 135 Growth in volumes to propel earnings Accumulate Gujarat
More informationTree House Education & Accessories
2QFY2016 Result Update Educational Services November 10, 2015 Tree House Education & Accessories Performance Highlights Y/E March (` cr) 2QFY16 2QFY15 % chg (qoq) 1QFY16 % chg (yoy) Net sales 57 50 15.1
More informationPRESS RELEASE Noida, Tuesday, February 9, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q3 & 9M FY2016 RESULTS JUBILANT
More informationJSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016
JSW Energy Ltd. Interest expenses dragged the bottom-line JSW Energy Ltd. (JSWEL) reported a mixed set of numbers for Q3 FY16 quarter. The company reported a consolidated total operating income of Rs.
More informationCipla Ltd. Rs. 741. India Equity Institutional Research Pharma. One off revenues from Nexium supply drives earnings HOLD. Target Price (Rs): 765
India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. Rs. 741 One off revenues from Nexium supply drives earnings HOLD Result highlights Cipla s Q1FY16 result beats our estimates due to higher
More informationHerzogenaurach, Germany, July 27, 2004 PUMA AG announces its consolidated nd
P Quarter P Half-Year For immediate release MEDIA CONTACT: INVESTOR CONTACT: U.S.A.: Lisa Beachy, Tel. +1 617 488 2945 Europe: Ulf Santjer, Tel. +49 9132 81 2489 Dieter Bock, Tel. +49 9132 81 2261 Herzogenaurach,
More informationHow To Understand And Value Gsk Pharma
2QFY2016 Result Update Pharmaceutical November 2, 2015 GlaxoSmithKline Pharma Performance Highlights Y/E Mar (` cr) 2QFY2016 1QFY2016 % chg (qoq) 2QFY2015 % chg (yoy) Net Sales 692 622 11.3 739 (6.4) Other
More informationGAIL (India) Ltd. INR 346
Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 India Equity Institutional Research Oil & Gas RESULT UPDATE GAIL (India) Ltd. INR 346 Good performance; Near term outlook looks stable BUY GAIL reported
More informationMangalam Cement Weak volumes marred performance
CMP* (Rs) 206 Market Cap. (Rs bn) 5.5 Free Float (%) 72 Shares O/S (mn) 26.7 Mangalam Cement Weak volumes marred performance Mangalam Cement (MCL) delivered a weak performance in 2Q but was marginally
More informationSUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH
Q2FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH SUPREME INDUSTRIES LTD Plastic Products BSE CODE:509930 NSE CODE: SUPREMEIND Bloomberg CODE: SIL IN SENSEX: 24,470 HOLD CMP Rs725
More informationMahindra CIE Automotive Ltd.
Apr-14 May-14 Jun-14 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15. Volume No.. 1 Issue No. 9 Automotive Ltd. April 08, 2015 BSE Code: 532756 NSE Code: MAHIND Reuters Code: MAHN.NS
More informationNavin Fluorine International
RESULTS REVIEW 2QFY16 29 OCT 2015 Navin Fluorine International INDUSTRY CHEMICALS CMP (as on 29 Oct 2015) Rs 1,579 Target Price Rs 1,800 Nifty 8,112 Sensex 26,838 KEY STOCK DATA Bloomberg NFIL IN No. of
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 440.20 Target Price 505.00 CASTROL INDIA LTD. Result Update (PARENT BASIS): Q3 CY15 NOVEMBER 9 th, 2015 12 th h, 2013 ISIN: INE172A01027 Index Details Stock Data Sector Oil Marketing BSE Code 500870
More informationDISCUSSION SUMMARY. Q3 & 9M FY16 Results Highlights. Consolidated Financials. About Us. Business Strategy & Outlook
DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q3 & 9M FY16 RESULTS UPDATE FEBRUARY 2016 DISCUSSION SUMMARY Q3 & 9M FY16 Results Highlights Consolidated Financials About Us Business Strategy & Outlook 2 SAFE
More informationFinancial Results. siemens.com
s Financial Results Fourth Quarter and Fiscal 2015 siemens.com Key figures (in millions of, except where otherwise stated) Volume Q4 % Change Fiscal Year % Change FY 2015 FY 2014 Actual Comp. 1 2015 2014
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 3562.00 Target Price 4000.00 INFOSYS LIMITED CONSOLIDATED Result Update: Q3 FY14 JANUARY 10 th 2014 ISIN: INE009A01021 Index Details Stock Data Sector IT BSE Code 500209 Face Value 5.00 52wk. High
More informationCONSOLIDATED STATEMENT OF INCOME
CONSOLIDATED STATEMENT OF INCOME 4 th quarter (a) 3 rd quarter 4 th quarter 2009 Sales 40,157 40,180 36,228 Excise taxes (4,397) (4,952) (4,933) Revenues from sales 35,760 35,228 31,295 Purchases, net
More informationBUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights
05 FEB 2016 Quarterly Update BUY Target Price: Rs 344 Muted Q3; Brands & Retail story to unfold Arvind s Q3 consolidated revenue at Rs 21.6 bn (Rs 20.7 bn in Q3FY15) was marginally below our estimate of
More informationCoal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015
17-Nov-14 17-Dec-14 17-Jan-15 17-Feb-15 17-Mar-15 17-Apr-15 17-May-15 17-Jun-15 17-Jul-15 17-Aug-15 17-Sep-15 17-Oct-15 Coal India Ltd. Subdued e-auction realization impacted profitability Coal India Ltd.
More informationSAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013
SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%
More informationMutual Fund Category Analysis Pharma Sector Funds
November 26, 2014 Mutual Fund Category Analysis Pharma Sector Funds Key Facts: What are they? Pharma Sector funds are equity oriented schemes investing predominantly in the pharmaceutical stocks. Pharma
More informationNovember 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP]
November 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP] Company Name: Idemitsu Kosan Co., Ltd. (URL http://www.idemitsu.com)
More informationInvestment Rationale
TM PTC India Financial Services Ltd IPO Analysis 15th Mar. 2011 Recommendation : Subscribe Sector NBFC Bidding Details Price Band Rs 26 - Rs 28 Face value Rs 10 Bid Size 250 and in multiple thereof Issue
More informationGranules India Ltd. INR 113
India Equity Institutional Research Pharma RESULT UPDATE Granules India Ltd. INR 113 Misses expectation BUY Result highlights Net sales for the quarter grew by a moderate 8% YoY to INR 3,449mn below our
More informationActuarial Society of India
Actuarial Society of India EXAMINATIONS November 2004 SUBJECT - 108: Finance and Financial Reporting Indicative Solution S-108 Page 1 of 7 1 D 2 C 3 B 4 D 5 D 6 A 7 B 8 C 9 B 10 D 11 Trade credit is short-term
More informationMaruti Suzuki. Source: Company Data; PL Research
Q3 results subdued, Outlook remains good; BUY January 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs4,103 Target Price Rs4,844 Implied Upside 18.1% Sensex 24,470 Nifty
More informationKhambatta Securities Ltd.
Attractive Valuation Strong Buy Sector : Bank Private Target Price : Rs 284 Current Market Price : Rs 230 Market Cap : Rs 1,337 bn 52-week High/Low : Rs 393/216 Daily Avg. Volume : 13.88 mn Shares in issue
More informationCipla Ltd. INR 542. India Equity Institutional Research Pharma. Muted quarter; outlook remains robust. Target Price (INR): 646. Potential Upside : 19%
India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. INR 542 Muted quarter; outlook remains robust BUY Result highlights Cipla s Q3FY16 Net Sales, EBITDA and PAT were below our estimates.
More informationHCC BUY. Infrastructure January 29, 2016
Jan-15 Mar-15 Apr-15 May-15 Jul-15 Aug-15 Sep-15 Nov-15 Dec-15 Jan-16 India Research Infrastructure January 29, 2016 QUARTERLY REVIEW Bloomberg: IN Reuters: HCNS.BO BUY Better margins drive earnings s
More informationEast India Hotels (EIH) Ltd Growing Strategically
East India Hotels (EIH) Ltd Growing Strategically BSE Code 500840 NSE Code EIHOTEL Bloomberg Code EIH@IN Face Value 10 CMP Rs 224 Market Cap Rs 11.7bn (as on August 27th 2004) Share Holding Pattern Others
More informationReliance Communication
3QFY214 Result Update Telecom February 11, 214 Reliance Communication Performance highlights (` cr) 3QFY14 2QFY14 % chg (qoq) 3QFY13 % chg (yoy) Net sales 5,43 5,394.2 5,31 1.9 EBITDA 1,845 1,887 (2.2)
More informationProsegur 9M 2013 Results
Prosegur 9M 2013 Results November 12th, 2013 Compañía de Seguridad S.A. all rights reserved 1 Highlights in the period The transfer to clients of the increase in the labour costs in Brazil (ARV) is being
More informationWipro BUY. Performance Highlights CMP. `573 Target Price `719. 2QFY2016 Result Update IT. Investment Period 12 Months. 3-year price chart
Wipro Performance Highlights (` cr) 2QFY16 1QFY16 % chg (qoq) 2QFY15 % chg (yoy) Net revenue 12,514 12,371 1.2 11,684 7.1 EBITDA 2,729 2,606 4.7 2,482 9.9 EBITDA margin (%) 21.8 21.3 51bp 21.2 56bp PAT
More informationChina Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
More informationHow To Value Hpl In India
Materials - Containers & Packaging Oct 01, 2015 Bloomberg Code: HPPL IN India Research - Stock Broking Backed by Acquisition, Set to Augment Market Share New acquisition: In FY15, HPPL acquired 100% of
More informationHCL Technologies BUY. Performance Highlights CMP. `857 Target Price `1,132. 1QFY2016 Result Update IT. 3-year price chart
1QFY2016 Result Update IT October 21, 2015 HCL Technologies Performance Highlights (` cr) Consl. 1QFY16 4QFY15 % chg (qoq) 1QFY15 % chg (yoy) Net revenue 10,097 9,777 3.3 8,735 15.6 EBIT 1,979 1,976 0.2
More informationAccumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH
Q3FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH Exide Industries Ltd(EIL) Automobile Ancillaries BSE CODE: 500086 NSE CODE: EXIDEIND Bloomberg CODE: EXID IN SENSEX: 23,759 Accumulate
More informationKotak Mahindra Bank Rs 685
India Equity Institutional Research BANKS RESULT UPDATE Kotak Mahindra Bank Rs 685 Smooth merger; benefits to accrue HOLD KMB s consolidated PAT for Q4FY15 stood at INR 9.5 that primarily on the back of
More informationUn-audited Consolidated Financials Results for the Quarter ended 30th September 2015.
8K MILES SOFTWARE SERVICES LTD Un-audited Consolidated Financials Results for the Quarter ended 30th September 2015. I For the Quarter Ended Rupees in Lakhs Year ended 30-Sep-15 30-Jun-15 30-Sep-14 31-Mar-15
More informationMinda Industries Ltd. INR 886
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Automobiles RESULT UPDATE Minda Industries Ltd. INR 886 Profit boosted by margins ACCUMULATE In Q3FY16, Minda Industries
More informationRamKrishna Forgings Ltd.
January 3, 2014 RamKrishna Forgings Ltd. Poised for Growth CMP INR 81 Target INR 117.2 Coverage Follow Up BUY Key Share Data Face Value (INR) 10 Equity Capital (in INR Million) 211.0 Market Cap (in INR
More informationPolaris BUY. Virtusa acquires majority in Polaris. Institutional Equity Research. November 05, 2015. Target Price Rs220. IT India.
CMP* (Rs) 204 Market Cap. (Rs bn) 20 Free Float (%) 71 Shares O/S (mn) 100 Polaris Virtusa acquires majority in Polaris Virtusa Corp has purchased promoter and Citi s stake in Polaris of 53% for Rs220
More informationStrong operational performance
ABB India Equity Research Engineering & Capital Goods February 8, 2016 Result Update Emkay Your success is our success Strong operational performance CMP Target Price Rs1,134 Rs1,407 ( ) Rating Upside
More informationCD Equisearch Pvt Ltd
Dec 10, 2015 Mayur Uniquoters Ltd. No. of shares (m) 46.3 Mkt cap (Rs crs/$m) 1943/291 Current price (Rs/$) 420/6.3 Price target (Rs/$) 475/7.1 52 week H/L (Rs.) 518/378 Book Value (Rs/$) 67.8/1.0 P/BV
More informationBharti Airtel Limited
Bharti Airtel Limited Registered Office: Bharti Crescent, 1, Nelson Mandela Road, Vasant Kunj, Phase II, New Delhi 110 070, India CIN: L74899DL1995PLC070609 T:+91-11-4666 6100, F:+91-11-4166 6137, Email
More informationUltraTech Cement Ltd.
Oct-11 Nov-11 Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 October 31, 212 COMPANY RESULTS REPORT REVIEW UltraTech Cement Ltd. Rich valuation overlooks strong performance
More informationFOR IMMEDIATE RELEASE February 4, 2016
FOR IMMEDIATE RELEASE February 4, 2016 Toshiba Announces Consolidated Results for the First Nine Months and Third Quarter of Fiscal Year Ending March 2016 TOKYO Toshiba Corporation (TOKYO: 6502) today
More informationFocus on fleet customers SAF-HOLLAND Annual Financial Statements 2013
Focus on fleet customers SAF-HOLLAND Annual Financial Statements 213 Detlef Borghardt, CEO Wilfried Trepels, CFO March 13, 214 Agenda 1 Financials 3 2 Appendix 21 2 Executive Summary 1 2 3 Group sales
More informationFor the year ended: 31 Mar 31 Mar (million ) 2011 2012 Change Net sales. 772.3 913.4 +18.3% Gross profit 637.0 755.5 +18.6%
Results highlights For the year ended: 31 Mar 31 Mar (million ) 2011 2012 Change Net sales 772.3 913.4 +18.3% Gross profit 637.0 755.5 +18.6% % of Net sales 82.5% 82.7% +0.2 pp Operating profit 132.1 152.3
More informationSTATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2015
Hinduja Global Solutions Limited (CIN: L92199MH1995PLC084610) Regd. Office : 171, Dr. Annie Besant Road, Worli, Mumbai - 400018. Contact no.: 022-2496 0707, Fax: 022-2497 4208 Website: www.teamhgs.com
More informationResults impacted by subdued demand
India Equity Research Agri Input & Chemicals January 25, 2016 Result Update Coromandel International Results impacted by subdued demand Emkay Your success is our success CMP Target Price Rs165 Rs225 (
More informationThird quarter results as of December 31, 2014. Investor presentation
Third quarter results as of December 31, 2014 Investor presentation February, 26 th 2015 Disclaimer Certain statements included or incorporated by reference within this presentation may constitute forwardlooking
More informationSulAmérica. UBS Global Healthcare Services Conference February 11-13, 2008 New York
SulAmérica UBS Global Healthcare Services Conference February 11-13, 2008 New York Disclaimer The material that follows is a presentation of general background information about Sul América S.A. ( SulAmérica
More informationSummary of Consolidated Financial Statements for the Second Quarter of Fiscal Year Ending March 31, 2012 (Japanese GAAP)
This document is a translation of the Japanese financial statements and is not in conformity with accounting principles of the United States. Summary of Consolidated Financial Statements for the Second
More informationBritannia Industries
Rally in Input costs near term drag, Maintain BUY June 20, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs2,641
More informationGlaxoSmithKline Consumer Healthcare
Strong pricing power, Attractive valuations "BUY" February 09, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs5,837
More informationwww.pvpglobal.com SECTOR: REALTY REPORTING DATE: 31 ST MAY, 2016 PVP Ventures Ltd
31 st May, 2016 TABLE 1 MARKET DATA (STANDALONE) (As on 31 st May, 2016) NSE Code PVP NSE Market Price ( ) 4.50 NSE Market Cap. ( Cr.) 118.85 Sector Realty Face Value ( ) 10.00 Equity ( Cr.) 245.05 52
More informationFebruary 2, 2016 Consolidated Financial Results for the Third Quarter of Fiscal Year 2015 (From April 1, 2015 to December 31, 2015) [Japan GAAP]
February 2, 2016 Consolidated Financial Results for the Third Quarter of Fiscal Year 2015 (From April 1, 2015 to December 31, 2015) [Japan GAAP] Company Name: Idemitsu Kosan Co.,Ltd. (URL http://www.idemitsu.com)
More informationShare gains with healthy margin uptick; Retain Buy
Colgate-Palmolive India Equity Research Consumers January 23, 2015 Result Update Emkay Your success is our success Share gains with healthy margin uptick; Retain Buy CMP Target Price Rs1,913 Rs1,940 (
More informationJust Dial Ltd Bloomberg Code: JUST IN
Communications - Internet Media Oct 14, 215 Bloomberg Code: JUST IN India Research - Stock Broking India s local search engine, warming up with add-on services Just Dial is now into a platform where people
More informationBharat Electronics. Strong margins, improved inflows! Source: Company Data; PL Research
Strong margins, improved inflows! January 28, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating Accumulate Price Rs1,228 Target Price Rs1,353
More informationConference call on 2014 half year results 13 August 2014
Conference call on 2014 half year results 13 August 2014 IMCD IMCD Group N.V. Disclaimer Forward looking statements This half year report contains forward looking statements. These statements are based
More informationFOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3.
FOSSIL GROUP, INC. REPORTS FOURTH QUARTER AND FISCAL YEAR 2014 RESULTS; Fourth Quarter Net Sales of $1.065 Billion; Diluted EPS Increases 12% to $3.00 Fiscal Year 2014 Net Sales Increase 8% to $3.510 Billion;
More informationTechno Electric & Engineering Limited
Engineering & Capital Goods Event Update Techno Electric & Engineering Limited Buy Wind business spin off will lead to value unlocking. Institutional Research CMP (`) 404 Target (`) 504 Nifty: 8,224 Sensex:
More informationMEDTRONIC, INC. WORLD WIDE REVENUE (Unaudited)
WORLD WIDE REVENUE ($ millions) 1 2 3 4 1 2 3 4 FY11 FY11 FY11 FY11 FY11 FY12 FY12 FY12 FY12 FY12 QTR 1 QTR 2 QTR 3 QTR 4 Total QTR 1 QTR 2 QTR 3 QTR 4 Total REPORTED REVENUE : CARDIAC RHYTHM DISEASE MANAGEMENT
More informationJubilant Life Sciences
Radiopharma, Niacin continues to drive sales, margins October 30, 2015 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs401 Target Price Rs578 Implied Upside 44.1% Sensex 26,838 Nifty
More informationAurobindo Pharma. Source: Company Data; PL Research
Earnings in line; Strong guidance for FY17E maintained February 10, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs691 Target Price Rs943 Implied Upside 36.5% Sensex 23,759 Nifty
More informationBata India Ltd. (BIL)
Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Q2FY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Bata India Ltd. (BIL) Cloudy quarter sunshine ahead;
More informationPiramal Enterprises Limited. Q3 FY2016 Results Presentation 8 February 2016
Piramal Enterprises Limited Q3 FY2016 Results Presentation 8 February 2016 Disclaimer Except for the historical information contained herein, statements in this presentation and any subsequent discussions,
More informationFOR IMMEDIATE RELEASE
FOR IMMEDIATE RELEASE O-I REPORTS FULL YEAR AND FOURTH QUARTER 2014 RESULTS O-I generates second highest free cash flow in the Company s history PERRYSBURG, Ohio (February 2, 2015) Owens-Illinois, Inc.
More informationAxis Bank. Strong core performance. Source: Company Data; PL Research
Strong core performance January 17, 2011 Abhijit Majumder abhijitmajumder@plindia.com +91 22 66322236 Umang Shah umangshah@plindia.com +91 22 66322242 Rating BUY Price Rs1,230 Target Price Rs1,600 Implied
More informationBlack Rose Industries Ltd Sector Industry 514183
Page 1 of 5 Company Profile Black Rose Industries Ltd was established in 1990 as sia Fab Limited, a textile manufacturing company. It is primarily in the business of chemical distribution and chemical
More informationSREI Infrastructure Ltd.
Report Date 22nd Oct, 2010 Company Name SREI Infrastructure Ltd. Price / Recommendation CMP: - `121 Buy (Medium Risk Medium Return) Company Background SREI Infrastructure Finance Ltd started its operations
More informationBiostime International (1112 HK) Expensive acquisition brings more challenges; maintain SELL
03/14 04/14 05/14 06/14 07/14 08/14 09/14 10/14 11/14 12/14 01/15 02/15 03/15 04/15 05/15 06/15 07/15 08/15 Biostime International Sep 22, 2015 Company Report Rating: SELL TP: HK$ 12.91 Share price (HK$)
More information